Project Grant FF205K105037

Cancer Immunoprevention Network Resource Coordinating Center Health Research, Inc. (Roswell Park Division) received a $1.65 million Cooperative Agreement from the National Cancer Institute under the Cancer Cause and Prevention Research program (CFDA 93.393) beginning September 1, 2025, through August 31, 2030. The awardee will serve as the Data and Resource Coordinating Center (DRCC) for the Cancer Immunoprevention Network (CIP-NET), providing centralized administrative infrastructure, data...

Federal Cooperative Agreement Summary The National Institutes of Health Office of the Director awarded a $1.86M Cooperative Agreement under the Research Infrastructure Programs (CFDA 93.351) to the University of California, Irvine, effective August 15, 2025, through July 31, 2030. The award establishes the Center for Modeling Non-Coding Disease Variants (NODIVA), which will develop targeted experimental disease models of non-coding genetic variants in mice and human pluripotent stem cells...

Federal Cooperative Agreement Summary Award Details: Iiam Corporation received a $1.25 million Cooperative Agreement from the National Science Foundation (NSF) Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), effective July 15, 2025, with completion targeted for June 30, 2027. The project will be performed in San Francisco, California. Products and Services: This Small Business Innovation Research (SBIR) Phase II project delivers a Natural Language Processing (NLP)-driven...

This SBIR Phase I project, awarded by the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084), aims to develop a method to turn on cancer immunotherapies only at the site of disease. The $275,000 award will support Synsorybio, Inc., a for-profit organization, in creating protein switches that activate immunotherapies in response to disease signals, rather than indiscriminately throughout the body. This approach seeks to improve the...

Federal Cooperative Agreement Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded The Regents of the University of California, San Francisco a $816,325 Cooperative Agreement on August 1, 2025, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to develop next-generation Unfolded Protein Response (UPR) inhibitory kinase inhibitors for Type 1 Diabetes (T1D) treatment. The project, which extends through June 30,...

Summary Weill Medical College of Cornell University received a $843,179 Cooperative Agreement from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), awarded August 1, 2025, with completion targeted for June 30, 2029. The award supports research to decode cell-specific impacts of epigenomic regulation and alternative splicing mechanisms during Type 1 Diabetes (T1D) progression....

Federal Cooperative Agreement Summary The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a Cooperative Agreement totaling $689,210 to the University of Colorado-Denver, effective August 1, 2025, through June 30, 2029, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The award funds research investigating the role of granular acidification in the pathogenesis of Type 1 Diabetes (T1D), with particular focus on...

Federal Cooperative Agreement Summary Window Therapeutics, Inc. received a $1.0 million Cooperative Agreement award from the National Science Foundation (NSF) under the Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) on July 15, 2025. The Small Business Innovation Research (SBIR) Phase II project, with a completion date of June 30, 2027, focuses on developing next-generation antibody-drug conjugates (ADCs) utilizing proprietary brush polymer technology. The core...

This SBIR Phase I award from the National Science Foundation (NSF) under the NSF Technology, Innovation, and Partnerships (TIP) program (CFDA 47.084) provides $273,550 to Biocognon LLC for the development of a combinatorial platform to discover improved molecular recognition components for use in therapeutic and diagnostic antibodies. The project aims to utilize synthetic biology, next-generation DNA sequencing, and computational biology to efficiently generate and screen libraries of antibody...

Federal Cooperative Agreement Summary Northern Michigan University (NMU) received a $194,787 Cooperative Agreement from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) effective September 18, 2025, with completion targeted for August 31, 2027. The award supports collaborative analytical and clinical validation of D2HGLO, a novel genetically encoded fluorescence resonance energy transfer (FRET)-based diagnostic and predictive tool designed...